Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanosonicsNNCSF +5.02%88 Days Sales Outstanding is 70.81 as of Dec. 2025, which is 10% above its 10-year median of 64.55. GuruFocus rates NNCSF with a GF Score™ of 88/100 and a GF Value™ of $3.52 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 810 Medical Devices & Instruments companies, Nanosonics ranks worse than 56.05% on this metric.
Nanosonics's average Accounts Receivable for the
six
months ended in Dec. 2025 was $26.4 Mil. Nanosonics's Revenue for the
six
months ended in Dec. 2025 was $67.9 Mil.
Hence, Nanosonics's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 70.81.
The historical rank and industry rank for Nanosonics's Days Sales Outstanding or its related term are showing as below:
NNCSF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.35 Med: 64.55 Max: 83.42
Current: 70.23
During the past 13 years, Nanosonics's highest Days Sales Outstanding was 83.42. The lowest was 41.35. And the median was 64.55.
NNCSF's Days Sales Outstanding is ranked worse than 56.05% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.28
vs NNCSF: 70.23
Nanosonics's Days Sales Outstanding
declined
from Dec. 2024 (79.37) to Dec. 2025 (70.81).
Nanosonics (OTCPK:NNCSF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Nanosonics Days Sales Outstanding Related Terms
Nanosonics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Nanosonics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Nanosonics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a Days Sales Outstanding of 70.81 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nanosonics and its competitors. This is 10% above median its historical median of 64.55. Over the past decade, Nanosonics' Days Sales Outstanding has ranged from 41.35 to 83.42. According to the industry distribution chart, Nanosonics ranks #454 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 56%.
Is Nanosonics' Days Sales Outstanding too high?
Nanosonics' current Days Sales Outstanding of 70.81 is 10% above median its 10-year median of 64.55. Over the past 10 years, this metric has ranged from a low of 41.35 to a high of 83.42. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.28. Nanosonics' value of 70.81 is 8.5% above this industry median. Based on the distribution chart, Nanosonics ranks #454 out of 810 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanosonics has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #454 out of 810 companies for Days Sales Outstanding. This places Nanosonics in the lower half of its industry. The industry median Days Sales Outstanding is 65.28. Nanosonics' value of 70.81 is 8.5% above this benchmark. Historically, Nanosonics' own Days Sales Outstanding has ranged from 41.35 to 83.42 over the past decade. While the company's 10-year median is 64.55 vs. the industry median of 65.28, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Days Sales Outstanding of 70.81 is 8.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Days Sales Outstanding is 70.81, which is 10% above median its own 10-year median of 64.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.52, compared to a current price of $2.30 — trading 34.7% below its estimated fair value. The current Days Sales Outstanding is 70.81, which is 10% above median its 10-year median of 64.55 and 8.5% above the Medical Devices & Instruments industry median of 65.28. Nanosonics' overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Days Sales Outstanding is 70.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.30 is trading 34.7% below its estimated GF Value™ of $3.52.
GuruFocus considers Nanosonics to be Significantly Undervalued.
Key valuation signals for NNCSF:
Days Sales Outstanding: 70.81 (10% above median its 10-year median of 64.55)
GF Value™: $3.52 vs. price of $2.30 (34.7% below fair value)
Industry Position: 8.5% above the Medical Devices & Instruments median (#454 of 810)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
88GF Score
Get the complete analysis for NNCSF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
